Daily highlights from the world of longevity and healthspan: Momentum for Parkinson\u2019s innovation grows with Vincere Biosciences<\/a> receiving a major The Michael J. Fox Foundation For Parkinson’s Research<\/a> grant to push its mitophagy-promoting therapy toward first-in-human studies.<\/p>\n Ochre Bio<\/a> and GSK<\/a> complete comprehensive human liver functional genomics datasets, paving the way for new target discovery and stronger translational insights.<\/p>\n HCW Biologics<\/a> kicks off its first-in-human trial of HCW9302, marking a key step forward in autoimmune disease therapeutics.<\/p>\n New Annovis Bio, Inc.<\/a> data link Alzheimer\u2019s co-pathology to faster cognitive decline in Parkinson\u2019s \u2013 and show buntanetap may deliver stronger cognitive benefits in amyloid-positive patients.<\/p>\n With a January Type C meeting scheduled with the FDA, Annovis Bio, Inc.<\/a> outlines next steps for buntanetap in Parkinson\u2019s dementia and confirms Phase 3 readiness in Alzheimer\u2019s.<\/p>\n Zymo Research Corp<\/a> and biomodal<\/a> team up to deliver integrated multi-omic sequencing, enabling genetic and epigenetic insights from a single sample.<\/p>\n
\nAn overview of how proposed The National Institutes of Health<\/a> cuts could impact US geroscience funding at a critical time for the field.<\/p>\n